⌕
Taysha Gene Therapies · TSHA · Nasdaq
Tenet 58 · Mixed
Compare
$4.00−1.48%At closeTenet 58 · Mixed
$4.00−0.06 (−1.48%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Taysha Gene Therapies (TSHA) Stock

Taysha Gene Therapies (TSHA) closed at $4.00 on Nov 17, 2026; its Tenet Score is 58 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

30 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$4.00
Nov 17, 2026
Market cap
$1.3B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
3.46 – 7.30
low → high · as of close, Nov 16, 2026
Tenet Score
58/100
Mixed · 340 Healthcare peers

Industry: Drugs

Taysha Gene Therapies Inc scores 58/100. Mixed. Strongest on financial health, quality is the soft spot versus 340 Healthcare peers. Insufficient inputs: Tenet 58 is built from 3 of 4 pillars, from 40% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=340
58/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
55
Quality
37
Health
84
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueCQualityDHealthBGrowth—MomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
3.7×
Sep 30, 2026 balance sheet
P/S
241.3×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
−54%
TTM through Sep 30, 2026
Operating margin
—
no operating margin on file
Net margin
—
Not meaningful: revenue is too small to measure a margin against.
Current ratio
18.56
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Taysha Gene Therapies Inc

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatmen…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 65 US ETFs · top wrappers by weightSee all ETFs holding TSHA →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Taysha Gene Therapies in?

Taysha Gene Therapies is in the Healthcare sector and the Drugs industry.

What is Taysha Gene Therapies' Tenet Score?

Taysha Gene Therapies' Tenet Score is 58 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.